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Delirium is an acute disorder of attention and cognition. It occurs across the life span,
yet it is particularly common among older adults, and is closely linked with underly-
ing neurocognitive disorders. Evidence is mounting that intervening on delirium may
represent an important opportunity for delaying the onset or progression of dementia.
To accelerate the current understanding of delirium, the Network for Investigation of
Delirium:Unifying Scientists (NIDUS) held a conference “AdvancingDeliriumResearch:
A Scientific Think Tank” in June 2019. ThisWhite Paper encompasses themajor knowl-
edge and research gaps identified at the conference: advancing delirium definition and
measurement, understanding delirium pathophysiology, and prevention and treatment
of delirium. A roadmap of research priorities is proposed to advance the field in a sys-
tematic, interdisciplinary, and coordinated fashion. A call is made for an international
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consortium and biobank targeted to delirium, as well as a public health campaign to
advance the field.
K EYWORD S
biomarkers, definition, delirium, dementia, diagnosis, measurement, pathophysiology, prevention,
public health campaign, treatment
1 INTRODUCTION
Delirium, an acute disorder of attention and cognition, is a common,
serious, and potentially preventable clinical syndrome in older persons.
Commonly occurring after acute illness, surgery, or hospitalization,
the development of delirium often initiates a cascade of events cul-
minating in loss of independence, increased morbidity and mortality,
and high health-care costs. Moreover, delirium has been associated
with long-term cognitive decline, including incident dementia.1–3 In
the United States, five older persons develop delirium each minute
annually, 2.6 million older adults are affected, costing the health-care
system >$164 billion.4 Given its adverse impact on functioning and
quality of life, delirium holds tremendous societal implications for the
individual, family, community, and health-care systems.
In recognition of the importance of delirium, the National Institute
on Aging (NIA) issued a request for applications to create collabora-
tive networks to advance delirium research in 2016. In response, the
Network for Investigation ofDelirium:Unifying Scientists (NIDUS)was
created with the overarching goal of developing a collaborative net-
work to advance scientific research on the causes, mechanisms, out-
comes, diagnosis, prevention, and treatment of delirium in older adults.
The network spans more than 27 institutions with an interdisciplinary
consortium of investigators dedicated to delirium research, who work
together to advance the field in an integratedandcollaborative fashion.
NIDUS provides research resources and training programs to enhance
these efforts (https://deliriumnetwork.org).
Despite the potentially modifiable burden of delirium on our pub-
lic health system, existing gaps in knowledge continue to limit funda-
mental new advances in prevention and treatment of delirium. Thus,
NIDUS, with support from theNIA, held a Scientific Think Tank on June
16, 2019. The goal of the Scientific Think Tank was to identify major
knowledge gaps in delirium research and to propose a roadmap with
priorities for futuredeliriumresearch. This reporthighlights thediscus-
sion and key priorities for the field of delirium,which spanned the areas
of delirium definition and measurement, pathophysiology, and preven-
tion and treatment.
2 ADVANCING DELIRIUM DEFINITION
AND MEASUREMENT
First and foremost, the field cannot advance without an accepted,
uniform, operationalized definition of delirium, and standardized
approaches to its measurement. The Scientific Think Tank participants
identified the following priority areas to advance the definition and
measurement of delirium: (1) consensus on the definition of delirium;
(2) development of a reference standard approach for the diagnosis
of delirium; (3) use of uniform, standardized measurement tools for
delirium case identification and severity rating across different care
settings; (4) identification of etiologic subtypes of delirium; and (5)
development and application of a core outcomes set (COS) for clinical
studies in delirium.
2.1 Refinement of the definition of delirium
The construct of delirium is complex. While inattention is the core
feature, considerable variability exists surrounding the presence and
degree of other symptom domains, such as altered level of arousal,
global cognitive dysfunction, and psychotic features. Currently,
there is no definitive diagnostic test for delirium; hence, detection
of delirium must rely on eliciting the key clinical features using a
combination of patient interview, cognitive testing, observation, and
informant history. However, the component features of delirium lack
explicit and accepted definitions, and there is little consensus on
operationalization and assessmentmethods of the individual symptom
domains. Reconceptualizing delirium would require expert panel
approaches, ideally combining clinical and psychometric approaches,
to identify and rank key domains and supporting features. Until
such consensus can be achieved, application of a smaller set of har-
monized delirium measures would help to speed advances in the
field.
2.2 Use of uniform, standardizedmeasurement
tools formeasuring delirium, and its severity
There is amarkedvariation inhowthe featuresof deliriumare assessed
in both clinical practice and research, ranging from subjective clinical
judgment to comprehensive methods supported by cognitive testing.5
Currently, more than 40 delirium instruments are in active use; often
rating different clinical features of delirium. Thus, our ability to com-
pare or combine results across studies using these disparate instru-
ments is severely impaired. To address this gap, we recommend more
rigorous development and validation of delirium instruments, particu-
larly those focused on operationalizing the reconceptualized definition
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of delirium. This should involve explicit descriptions of the constructs
and domains, along with the use of quantitative, objective instru-
ments that are well validated using formal psychometric approaches
(ie, reliability, validity, discriminatory power, and normative data). At
the same time, these new approaches need to consider the challenges
of delirium assessment in real-world practice. This, in turn, will inform
the development of more reliable, robust, and standardized assess-
ments of delirium presence and delirium severity.6 The NIDUS Mea-
surement Harmonization Core provides detailed information cards
on delirium instruments, and tools to harmonize existing measures
(https://deliriumnetwork.org/measurement).
2.3 Development of a reference standard for
diagnosis of delirium
The uncertainty concerning the conceptualization and measurement
of delirium has had important implications for the delirium reference
standard used in research, because there is no common reference stan-
dard for delirium that is uniformly applied across studies at this time.5
We recommend detailed and explicit documentation of the reference
standard assessment process in all studies, including specification of
the methods used to assess the individual features of delirium. A col-
laborative approach toward developing and refining a common refer-
ence standard, incorporating agreed-upon assessment methods, and
a robust diagnostic algorithm is critical to advance delirium research.
Such an approach will increase the consistency of case ascertainment
and improve the generalizability and comparability of research findings
across studies.7,8
2.4 Identification of etiologic subtypes of delirium
Current measures capture different phenomenological subtypes
(eg, hyperactive, hypoactive, subsyndromal), but do not capture the
heterogeneity of the underlying etiology. The ability to distinguish
the etiologic subtypes of delirium will be critical to develop more
effective and targeted delirium interventions; an approach that is
similar to pathophysiologically targeted advances in other fields
such as cancer and heart disease. Future assessment of delirium
should incorporate standardized strategies to evaluate for the pres-
ence of important physical examination and laboratory findings, and
assessment of other potential contributors (delirium risk factors
such as medications, dehydration, metabolic derangements, infec-
tions, organ failure, and underlying dementia), comorbid diseases,
and detailed substance use histories. Due to the fact that delirium
is typically of multifactorial etiology, the development of rigorous
approaches to identify the main cause(s) of delirium will be helpful.
Biomarkers, including electrophysiologic, fluid (cerebrospinal, blood),
and neuroimaging, may contribute to better etiologic discrimina-
tion in the future. Although such additional approaches may prove
too time consuming and expensive for standard clinical practice,
it will be important to adopt detailed biomarker analysis of differ-
ent etiologic subtypes in clinical research settings to elucidate the
underlying pathophysiology and to develop effective treatments for
delirium.
2.5 Application of a core outcomes set for clinical
studies in delirium
Another keymeasurement issue for delirium investigation is consistent
adoption of a standardized approach to measuring delirium-related
outcomes relevant to delirium research. This issue is important to
advance clinical trials, and prognostic and pathophysiologic studies of
delirium. A COS represents a minimum set of outcomes (ie “what” to
measure) that all trials in a specific field should alwaysmeasure. A COS
may be accompanied by recommendations for specific measurement
instrument(s) to be used for each outcome (ie, “how” to measure). This
approach has been applied to many clinical conditions and treatment
approaches to promote consistency and comparability across clinical
trials, to improve clinical decision making, and to improve efficiency
and generalizability of research findings.9-13 A COS is typically devel-
oped through rigorous generation of outcomes/measures (eg, via
systematic review and expert input) and consensus techniques (eg,
modified Delphi method) with engagement of key stakeholders, such
as patients, caregivers, clinicians, researchers, regulators, research
funders, and industry representatives. An international effort is
under way to develop delirium COS, the Del-COrS study14 in four
patient groups: (1) critical care, (2) acute hospitalization without
critical care admission, (3) palliative care, and (4) older adults in
long-term care or living in the community. Once developed, this COS
will provide an important resource to advance clinical research in
delirium.
3 ACCELERATING UNDERSTANDING OF
DELIRIUM PATHOPHYSIOLOGY
The pathophysiology of delirium remains unclear; yet an under-
standing of this is essential for developing pathophysiologically tar-
geted treatments essential for precisionmedicine. The Scientific Think
Tank recognized that elucidating the pathophysiology of delirium
will benefit from both development of laboratory animal models, as
well as human fluid (blood, cerebrospinal), neuroimaging, and neuro-
physiological biomarker studies. As each of these assessment meth-
ods provides only partial insights into the complex biology of delir-
ium, transdisciplinary approaches that synthesize data from multiple
approaches provide an opportunity for a broader understanding of
delirium.
3.1 Laboratory animal models of delirium
Laboratory models are required to evaluate potential mechanisms
of delirium-like behavior in vulnerable animals in an experimental
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setting, an approach that would not be feasible or ethical in humans.
To enhance usefulness, animal models should be expected to meet
criteria for construct validity (ie, precipitated by etiological factors
known to contribute to delirium) and face validity (eg, observing
cognitive and behavioral changes seen in human delirium). Specifically,
these models should closely approximate the accepted criteria for
delirium: (1) presence of acute and transient cognitive changes not
better explained by an underlying neuropathological condition;15 (2)
ideally, demonstration of a fluctuating course;16 and (3) instigation
by acute physiologic stimuli, such as surgery, inflammation, infection,
hypoxia, medication(s), or hypoglycemia. Relevant animal models
should not be held to higher standards than those for other complex
and heterogeneous neurological disorders such as mouse models of
dementia, schizophrenia, or autism, which are widely used despite
not representing these full clinical syndromes. What is essential is
that delirium features are reproducibly demonstrable in blinded, ran-
domized, and appropriately powered experiments. Cross-validation of
these behavioral changeswith humanneurophysiologicalmeasures (eg
electroencephalogram [EEG] changes),17,18 may provide furthermodel
validation, and may provide insights into underlying pathophysiologic
mechanisms.
Several animal models have been developed and while demonstrat-
ing some features of delirium in the setting of sepsis,19 surgery,20
and delirium superimposed on dementia,21 all would benefit from
further validation. These models have proven useful in providing
a conceptual framework for how peripheral changes in inflamma-
tion, blood-brain barrier permeability,22 and metabolism can bring
about acute cognitive changes.23 However, to reach their potential,
considerable work is required to define the cellular and molecular
pathways that lead to acute neuronal dysfunction, and determine
how neuronal dysfunction leads to alterations in brain networks and
behavior. Deliriummay arise by different mechanisms across different
clinical settings, and each settingmay require differentmodel systems,
although some commonalities in mechanisms are likely. Shared behav-
ioral endpoints, for example focusing on attention processing, should
also be adopted and standardized across laboratories to provide
targeted information about selected cognitive domains of relevance
to delirium. With the further development and refinement of these
model systems, we anticipate significant future progress in elucidating
mechanisms of neuroinflammation and neurotransmitter modulation
on brain dysfunction. Exploring the roles of altered neurovascular
coupling and disrupted brain energy metabolism in delirium are
also priority areas. Ultimately, these mechanistic studies hold great
promise to identify key targets for interventions in future delirium
clinicaltrials.
3.2 Fluid (blood, cerebrospinal) and
neurophysiological biomarkers of delirium in humans
In addition to laboratory animal models, biomarkers may pro-
vide insights into the molecular mechanisms and systems biology
underlying delirium and its associated complications in humans.
Although there are increasing numbers of studies collecting biospeci-
mens from patients, these studies vary in sample size, clinical settings
(eg, peri-operative, intensive care unit), types of samples collected (eg,
blood, cerebrospinal fluid, urine) and specimen processingmethods. As
a result, it has beendifficult to identify biomarkers that are consistently
associated with delirium.24,25 In addition, new delirium biomarkers
may emerge from neuroimaging (eg, structural or functional magnetic
resonance imaging [MRI]) or neurophysiology (eg, resting-state, intra-
operative, or sleep EEG). Recent studies demonstrate patients with
postoperative delirium exhibit neurophysiological patterns detectable
by modern signal processing and machine learning methods.26 Future
researchwouldbenefit fromstandardized approaches to specimen col-
lection, analyses, data reporting, imaging sequences, and biomarker
assessment.
3.3 International DeliriumBiomarker Consortia and
Biobanks
One of the proposed ways to further stimulate biomarker
research is through an international biomarker consortium. Such
an effort has the potential to build large-scale data and speci-
men banks to conduct systems biology, -omics (eg, proteomics,
metabolomics), and machine learning studies to accelerate the
advancement of scientific knowledge in the field. Similar consortia
and biobanks already exist for a number of other conditions and
diseases; this approach is advocated in the National Institutes of
Health (NIH) Open Science initiative (https://www.nlm.nih.gov/
NIHbmic/nih_data_sharing_repositories.html). Many consortia already
exist for dementia, such as the Alzheimer’s Disease Neuroimaging
Initiative (ADNI),27 the Mark Vascular Contributions to Cognitive
Impairment and Dementia (MarkVCID) Biomarker Development and
Validation Consortium for Small Vessel Disease,28 the Molecular
Mechanisms of the Vascular Etiology of Alzheimer’s Disease (M2OVE
AD),29 the Dementia with Lewy Bodies (DLB) Research Consortium,
and the Advancing Research and Treatment for Frontotemporal
Lobar Degeneration (ARTFL) consortium.30 The purpose of these
consortia is to facilitate assembly of large patient samples (with
data and specimens) for future studies. Following these examples, an
international delirium consortium will enable systematic collection
of clinical, biomarker, electrophysiologic, and neuroimaging data;
standardization and harmonization of variables and approaches;
and more detailed investigation of delirium pathophysiology, thus
paving the way for precision-based approaches to prevent and treat
delirium.
NIDUS provides important resources to facilitate the devel-
opment of these consortia and biobanks. The NIDUS Research
Hub (https://deliriumnetwork.org/delirium-research-hub) provides a
detailed, indexed listing of >200 delirium studies in an effort to cat-
alyze collaborative studies, data synthesis and meta-analyses, system-
atic reviews, and secondary analyses.
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4 PREVENTION AND TREATMENT OF
DELIRIUM
4.1 Multicomponent, sequential approaches
Given the complex, heterogeneous, and multifactorial causation of
delirium, it is not surprising that single drug or non-pharmacologic
intervention strategies have not demonstrated effectiveness for delir-
ium prevention or treatment. In terms of what is known already, mul-
ticomponent, non-pharmacologic strategies, such as theHospital Elder
Life Program (HELP, hospitalelderlifeprogram.org) or the ICU Libera-
tion ABCDEF bundle have demonstrated at least partial effectiveness,
with >50% reduction in delirium across multiple studies.31-33 These
strategies should be further evaluated to determine minimum ele-
ments, doses required, and optimal implementation strategies. Novel
approaches worth evaluating include new non-pharmacologic strate-
gies, with recent examples including prehabilitation prior to elective
surgery and use of decision-support technology to facilitate manage-
ment. In terms of pharmacologic approaches, further evaluation of
intriguing drugs should be advanced, including dexmedetomedine,34
caffeine, acetaminophen, melatonin and agonists, and other sleep
enhancement approaches.
Future treatment targets will arise out of pathophysiological
research, and it is likely that treatments will need to be multicompo-
nent. An evidence-based, multicomponent bundle that encompasses
bothnon-pharmacological andpharmacological interventions targeted
to proven risk factors and pathophysiologic pathways should be con-
sidered. Consideration of sequential approaches, targeting multiple
biologic targets on delirium pathways, might prove a more effective
approach than treatments aimed at a single target.
4.2 Novel trial designs
The traditional randomized controlled trial (RCT) is not well suited
to addressing multiple interventions in heterogeneous populations
who may have different outcomes and responses to therapeutic inter-
ventions. Recent innovations in clinical trial design help to overcome
limitations of the traditional RCT. Bayesian or adaptive trials allow
continual design modifications while the trial is ongoing, allowing
customization to multiple subpopulations and interventions.35 This
approach allows for prespecified modifications to key aspects of the
trial as information regarding patient characteristics and outcomes
accumulate, and areas of uncertainty regarding the true efficacy of the
interventions being studied are reduced. Aspects that can be modified
include sample size, randomization ratio, number of treatment groups,
treatment administered or treatment dose, and the patient subpopu-
lation being considered (allowing selective recruitment of populations
most likely to benefit).35 Platform trials are a type of adaptive design
that may be of particular utility in delirium research as they evaluate
multiple treatments simultaneously, based on the assumption that
populations of patients with disease are heterogeneous and may
respond differently to the same intervention.36
Complementary to individualized precision medicine are more
broad-based approaches to delirium prevention and treatment. RCTs
examining efficacy—including adaptive designs—are useful to evaluate
the treatment effect of interventions applied to selected populations
under controlled conditions. By contrast, pragmatic RCTs assess the
clinical effectiveness of interventions applied broadly in routine clinical
care, and are useful to establish evidence-based guidelines and prac-
tice standards.37,38 The most appropriate way to evaluate these broad
approaches to care, such as clinical algorithms or hospital-wide delir-
ium prevention and management pathways, is to assess their impact
on a population under the same conditions as in actual practice.38 His-
torically, researchers have done this by randomizing interventions at
the level of a patient grouping (or cluster), rather than at the level of
the individual patient. Most often, in delirium research, patients are
clustered at the level of a hospital, ward, intensive care unit (ICU), or
other clinical setting. Other randomized pragmatic designs are nested
in cohort studies or registries, such that patient data and outcomes
are collected from trial and administrative databases, rather than col-
lected by research staff.39 The advantages of this approach are that the
cohort provides a pool from which patients can be recruited, multiple
interventions can be tested simultaneously, and control arm outcomes
are available.39 Similarly, registry-based randomized trials use clinical
databases (ie, administrative datasets retained by hospitals, clinical tri-
als networks, health-care systems, etc) as a platform for case records,
data collection, randomization, and follow-up, resulting in improved
efficiency and cost. The limitations of registry-based randomized trials
include concerns about the quality of the registry data due to lack of
blinding, standardized patient management procedures, and standard-
ized outcomes assessments.40 To develop new treatments for delir-
ium, researchers hope to target pathophysiologic mechanisms to treat
specific etiologic phenotypes of delirium. Testing these customized
interventions requiresmodifications to traditional clinical trial designs,
which may be accomplished using adaptive or Bayesian designs. How-
ever, beyond individual patients, there remains limited evidence about
what constitutes best practice at the institutional level. To guide broad-
based practice, large pragmatic trials are required to establish the clini-
cal effectiveness of system-widemeasures focusedondeliriumpreven-
tion and treatment.
5 INCREASING DELIRIUM AWARENESS
AND FUNDING
Delirium is now increasingly recognized as a public health priority,
an often-preventable condition ready for quality improvement efforts
across clinical settings. Delirium has emerged as a focus of preven-
tion for the Age Friendly Hospitals Initiative by the Institute of Health-
care Improvement.41 The American Association of Retired Persons
is developing public education materials about delirium as part of its
Global Brain Health Initiative. The National Quality Forum has devel-
oped delirium quality measures for hospitals. Alzheimer’s & Dementia:
The Journal of the Alzheimer’s Association has recognized delirium as an
important and unexplored opportunity for dementia prevention, and
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TABLE 1 A roadmap for advancing delirium research: Proposal from the NIDUS Scientific Think Tank
Domain Priority areas Description
Definition and
measurement
Refining the construct of
delirium
• Consensus approaches to identify key domains and supporting features of
delirium




• Small set of standardized, well-validated instruments for delirium




• Consensus approach to develop common reference standard definition and
assessment




• Standardized approaches to identify underlying contributors to delirium
• Incorporate biomarkers
• Use subtyping to target treatment
Core outcomes set for
delirium studies
• Specified outcomes for clinical trials and studies of delirium
• Tailored to specific clinical settings
• Consistent application
Pathophysiology Laboratory animal models for
delirium
• Experimental induced delirium in vulnerable animal
• Meet construct validity (accepted precipitating factor) and face validity (manifests
some delirium domains)
• Test hypothesized pathophysiologic mechanisms to identify targets for future
treatment trials
Biomarkers for delirium in
humans
• Standardized approaches for specimen collection, analyses, and reporting
• Novel biomarkers: fluid, neuroimaging, electrophysiologic




• Large-scale data and specimen banks to facilitate systems biology, -omics (eg,
proteomics, metabolomics), andmachine learning studies
• Systematic collection of clinical, biomarker, electrophysiologic, neuroimaging





• Novel approaches to prevention
• Multicomponent treatment bundle, including nonpharmacologic and
pharmacologic interventions targeted to proven risk factors and pathophysiologic
pathways
• Sequential treatment approaches, targetingmultiple biologic targets on pathways
Novel trial designs • Adaptive trial designs (eg, Bayesian, platform) that allow customizationwhile trial
ongoing to refine interventions and study subpopulation
• Pragmatic trials to evaluate system-wide or large-scale management strategies
• Registry-based clinical trials to improve efficiency and reduce costs
Public health
campaign
Educational and public health
campaigns
• Public education to increase awareness, improve research funding, and address
ageism and the stigma of delirium and dementia
• Workforce development and training of health-care professionals
• Larges-cale implementation of effective approaches for prevention and
management of delirium
• FollowAlzheimer’s disease approach
• Define societal impact and economic costs of delirium
• Health policy efforts to advance delirium awareness, prevention and clinical care,
and research
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has established a special topic section to raise the visibility of delir-
ium in the Alzheimer’s disease (AD) research community. There is a
strong international consensus about the need for a grassroots effort
to improve the public’s awareness of, and increase funding for, delir-
ium using a similar public health campaign model that has driven AD
prevention into the international forefront of health policy planning.
The International Drive to Illuminate Delirium (IDID) seeks to advance
the field of delirium along five pillars: awareness, policy, diagnosis, bur-
den, and biology. This campaign will draw upon the same methods and
procedures used to increase public awareness and research funding
for AD. The initial core functions for the campaign include the assem-
bly of international experts, from multiple disciplines, participating in
work groups to develop plans that will lessen the burden due to delir-
ium over the next 10 years. This campaign seeks to produce a series of
consensus and implementation documents that will identify key chal-
lenges, potential demonstration projects, research priorities, and cost
estimates to help reduce the burden of dementia due to delirium.
6 A ROADMAP FOR DELIRIUM RESEARCH
Based on the discussion at the NIDUS Scientific Think Tank, Table 1
provides a potential roadmap of research priorities to advance the
field. This represents a compilation of the important gaps in knowledge
needed to move the delirium field forward. Systematic and thorough
investigation of the issues and questions identified here will lay the
groundwork for fundamental advances in delirium research and clinical
practice.We hope this roadmapwill provide a call to action for the field
and catalyze continued advances in this important and neglected area.
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